Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 15/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401884 | 0.81 | F10 (0.62) | NPC1RAB9AF10SMN1; SMN2KLKB1 | |
| SCHEMBL9928635 | 0.81 | F10 (0.63) | F10KLKB1 | |
| SCHEMBL9928692 | 0.81 | F10 (0.62) | KMT2AF10KLKB1 | |
| SCHEMBL9979761 | 0.80 | F10 (0.71) | NPC1RAB9AKMT2ANPSR1F10 | |
| SCHEMBL5407030 | 0.79 | F10 (0.63) | F10KLKB1 | |
| SCHEMBL5395001 | 0.79 | F10 (0.64) | F10KLKB1 | |
| SCHEMBL5398861 | 0.77 | F10 (0.53) | NPC1RAB9AF10KLKB1 | |
| SCHEMBL5407352 | 0.77 | F10 (0.53) | NPC1RAB9AF10KLKB1 | |
| SCHEMBL2360325 | 0.74 | F10 (0.74) | F10KLKB1 | |
| SCHEMBL2321697 | 0.72 | F10 (0.61) | NPC1RAB9AF10KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | claimed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | claimed |